Revolution Medicines began shipping daraxonrasib to physicians and patients under an FDA-authorized early access program for pancreatic cancer, CEO Mark Goldsmith said. The drug is still investigational, but Revolution reported Phase 3 results earlier this year showing patients lived nearly twice as long as those on standard chemotherapy. The company said it is responding to patient demand since the mid-April disclosure of the Phase 3 outcome. Early access in pancreatic cancer typically accelerates availability for patients with limited options while a full regulatory path remains pending. Daraxonrasib is designed as a life-extending therapy in a disease area where incremental survival gains have often been measured in months rather than large step-changes. The shipping announcement increases scrutiny on how durable the survival benefit is across subgroups and endpoints as regulators prepare for eventual review.